Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ABOS
vs
S&P 500
ABOS
S&P 500
Over the past 12 months, ABOS has underperformed S&P 500, delivering a return of +0% compared to S&P 500's +17% growth.
Stocks Performance
ABOS vs S&P 500
Performance Gap
ABOS vs S&P 500
Performance By Year
ABOS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Acumen Pharmaceuticals Inc
Glance View
Acumen Pharmaceuticals is a clinical-stage biotechnology company that is developing treatments for Alzheimer’s disease. Its main idea is to target toxic forms of amyloid-beta in the brain, especially soluble oligomers, which the company believes play an important role in the disease process. The company does not sell a broad range of drugs; it is focused on advancing a small number of drug candidates through testing and development. The company’s lead product is an antibody therapy designed to bind these harmful amyloid-beta proteins and help clear them from the brain. Acumen’s customers are not patients directly in the commercial sense yet, because the company is still in the development stage. Its work is funded mainly through research and development partnerships, capital raising, and eventually, if a treatment succeeds, sales to hospitals, doctors, and healthcare systems through the drug market. What makes Acumen’s business different is its narrow scientific focus. Instead of trying to build a large drug portfolio, it is betting on one specific disease mechanism in Alzheimer’s and on biologic drugs that can be tested as disease-targeted therapies. That puts the company in the high-risk, high-reward part of biotech, where value depends on moving a few experimental medicines through clinical development and, if successful, into commercial use.
